DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ibrexafungerp
Ibrexafungerp
(KPIC) PPO and Out-Of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier
Emergence of Antifungal Resistance and the Promise of New Antifungal Agents
NDA Multi-Disciplinary Review and Evaluation - NDA 214900 BREXAFEMME (Ibrexafungerp)
Novel Antifungal Agents in Clinical Trials[Version 1; Peer Review: Awaiting Peer Review]
Ibrexafungerp
Candida Auris: a Bibliometric Analysis of the First Ten Years of Research (2009–2018)
In Vitro Activity of Ibrexafungerp Against a Collection of Clinical
Development of a Protocol to Question Health Care Workers Considering Oral Thrush in Infants
Prevalence and Therapeutic Challenges of Fungal Drug Resistance: Role for Plants in Drug Discovery
Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs August 2020
Aspergillus Isolates from Patients with Chronic Pulmonary Aspergillosis
A Phase 2B, Dose-Finding Study Evaluating Oral Ibrexafungerp in Moderate to Severe Acute Vulvovaginal Candidiasis (DOVE)
Ibrexafungerp: a First-In-Class Oral Triterpenoid Glucan Synthase Inhibitor
Assessment of Aspergillus Kinases As Targets for Antifungal Drug Discovery
Appendix B - Product Name Sorted by Applicant
New Drugs, Inhaled Antifungals, and Management of Resistant Pathogens Sarah E
Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria
Novel Small Molecule Antifungals for Invasive Fungal Infections
Top View
FDA Antifungal Workshop Transcript, Thursday, August 4, 2020
Alphabetical Listing by Therapeutic Category Dod UNIFORM
Performance Standards for Antifungal Susceptibility Testing of Yeasts
Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
Drug Coverage Guidelines – Oxford Clinical Policy
Corporate Presentation
Cornely Mycoses 2019 Defining Breakthrough
Appendix a - Product Name Index
Review of Current Antifungal Pipeline Developments
Medical Necessity Criteria for Pharmacy Edits, 5.01.605
P114780 SCYX June 29 Master Deck V123 0628 Vf
2021 Standard Opt out with ACSF
Clinical Trial Protocol!
Orange Book Cumulative Supplement 7 July 2021
Candida Auris Urinary Tract Infections and Possible Treatment
A Novel Oral Triterpenoid Antifungal In
Ibrexafungerp (Formerly SCY-078) ASM Microbe 2019 San Francisco, CA June 2019
Medicines in Development ꟷ Antimicrobial Resistance (AMR)
Rxoutlook® 1St Quarter 2021
2021 Sutter Health|Aetna
Methodology for the 2020 AMR Benchmark
(SCY-078), Against Multidrug- and Pan-Resistant Candida Auri
Hope on the Horizon: Novel Fungal Treatments in Development Adriana M
SCY- 078) with Voriconazole in Patients with Invasive Pulmonary Aspergillosis Status: Recruiting
Therapeutic Tools for Oral Candidiasis: Current and New Antifungal Drugs